4 251

Cited 11 times in

Clinical significance of serum levels of immune-associated molecules, uric acid and soluble MHC class I chain-related molecules A and B, as diagnostic tumor markers for pancreatic ductal adenocarcinoma.

 Hye Won Chung  ;  Jong-Baeck Lim 
 CANCER SCIENCE, Vol.102(9) : 1673-1679, 2011 
Journal Title
Issue Date
Algorithms ; Biomarkers, Tumor/blood ; CA-19-9 Antigen/blood ; Carcinoma, Pancreatic Ductal/diagnosis* ; Carcinoma, Pancreatic Ductal/immunology ; Female ; Histocompatibility Antigens Class I/blood* ; Humans ; Male ; Middle Aged ; Pancreatic Neoplasms/blood ; Pancreatic Neoplasms/diagnosis* ; Sensitivity and Specificity ; Uric Acid/blood*
Immune-associated molecules play important roles in cancer development and progression. The aims of this study were to determine the diagnostic utility of uric acid (UA) and soluble MHC class I chain-related molecules A (sMICA) and B (sMICB) in pancreatic ductal adenocarcinoma (PDAC) compared with those of cancer antigen 19-9 (CA19-9), the most commonly available tumor marker for PDAC. We evaluated serum levels of UA, sMICA and sMICB along the carcinogenic process of PDAC obtained from 148 individuals composed of normal (n = 70), chronic pancreatitis (n = 23) and PDAC (n = 55), and compared them with those of CA19-9. We also evaluated the correlations of these biomarkers with tumor size, resectability or TNM stage, and tested logistic regression to ascertain the potential usability of these markers for the detection of PDAC. We also investigated the correlations among these biomarkers. Serum UA, sMICA and sMICB differed significantly according to groups (Kruskal-Wallis, P < 0.05), and were closely correlated with the development of PDAC. Serum sMICA were correlated with distant metastasis and sMICB were correlated with unresectability. Sensitivity and specificity of sMICA and sMICB were higher than CA19-9, and a multi-maker panel using all tested markers (UA, sMICA, sMICB and CA19-9) demonstrated the best potential for detecting PDAC (94.2% sensitivity at 93.3% specificity). The three tested markers also showed added diagnostic potentials to overcome the limitation of CA19-9 by differentiation of PDAC from non-cancerous conditions when CA19-9 is inappropriate. In conclusion, serum UA, sMICA and sMICB might be useful screening or differential diagnostic biomarkers for PDAC to complement CA19-9.
Full Text
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Laboratory Medicine (진단검사의학교실) > 1. Journal Papers
1. College of Medicine (의과대학) > Dept. of Internal Medicine (내과학교실) > 1. Journal Papers
Yonsei Authors
Lim, Jong Baeck(임종백) ORCID logo https://orcid.org/0000-0003-0419-0422
Chung, Hye Won(정혜원)
사서에게 알리기


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.